BrainStorm Cell Therapeutics Inc.

332 articles with BrainStorm Cell Therapeutics Inc.

• Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility

  10/26/2020

  Rapid Reshore & Development and BrainStorm Cell Therapeutics, Inc announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® in the U.S.

• BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Outcomes at the Virtual New York Stem Cell Foundation Conference

  10/19/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF Exosomes: A Novel Therapeutic Modality in the Mouse LPS-induced ARDS model Analysis" at the NYSCF Conference Meeting, being held virtually.

• BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update

  10/15/2020

  New senior executives strengthen regulatory and market access capabilities as the Company prepares to transition to a commercial organization

• BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa

  10/12/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the Mesa, being held virtually October 12-16, 2020.

• BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting

  9/30/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced the presentation of a poster titled, "Advancing NurOwn® for ALS: Phase 3 Clinical Trial Design" at the Annual Northeast ALS Meeting, being held virtually.

• BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing

  9/29/2020

  Company continues building its executive team and commercial capabilities prior to ALS Phase 3 clinical trial completion and topline data readout in Q4 2020

• BrainStorm to Present at Scientific Conferences in September

  9/3/2020

  Advanced Therapies & Expo 2020 on September 9 CIRM 2020 Grantee Meeting on September 14 Collaborations That Transform MS Webinar on September 24   NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it will deliver virtual presentations during Advanced Therapies & Expo 2020, September 9, at the 2020 CIRM Grantee Meeting, September 14,

• BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs

  9/2/2020

  Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4

• BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis (MS)

  8/25/2020

  Presentation at ECTRIMS/MSVirtual2020 to Inform Analysis of Clinical Outcomes in Ongoing Phase 2 Trial of NurOwn® in Patients with Progressive MS

• BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's Disease

  8/19/2020

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the publication of a manuscript titled, "Effects of MSC-NTF cells on T and B regulatory cell function in ALS" in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

• BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference

  8/10/2020

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern , MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40 th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13,

• BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update

  8/5/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the second quarter and first half ended June 30, 2020, and provided a corporate update.

• BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update

  7/27/2020

  BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020 , and provide a corporate u

• BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS

  7/23/2020

  Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model

• BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program

  7/8/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader webinar on its Alzheimer's Disease program at 8:15 AM Eastern Time.

• BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS

  7/2/2020

  BrainStorm Cell Therapeutics Inc. announced that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn® in amyotrophic lateral sclerosis.

• BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar

  7/1/2020

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key Opinion Leader (KOL) webinar on the Company's Alzheimer's disease (AD) clinical program on Wednesday July 8th at 8.15am ET.

• BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease

  6/24/2020

  Company will host a Key Opinion Leader call and webcast to discuss the newly announced Alzheimer's Disease program on July 8, 2020 at 8:15 AM ET

• BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index

  6/23/2020

  BrainStorm Cell Therapeutics Inc. announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020.

• BrainStorm Granted SME Status by the European Medicines Agency

  6/15/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that it has been granted Small and Medium-Sized Enterprise status by the European Medicines Agency’s Micro, Small and Medium-Sized Enterprise office.